NovoCure Limited (NASDAQ:NVCR) traded at $104.46 at last check on Tuesday, Sep 15, making an upward move of 6.92% on its previous day’s price.
Looking at the stock we see that its previous close was $97.7 and the beta (5Y monthly) reads 1.52. The company has a 12-month trailing PE ratio of 34820. In terms of its 52-week price range, NVCR has a high of $98.84 and a low of $53.4. The company’s stock has gained about 38.01% over that past 30 days.
There have been no upward or downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the NVCR stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 50% Buy.
Based on estimates by 8 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 3 have rated the NovoCure Limited (NVCR) stock as a Hold, while 4 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas 1 suggests the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the NVCR stock currently stands at 0, and the current price level is 26.73% off its SMA20 and 40.72% from its 50-day simple moving average. The RSI (14) is pointing at 87.26 while the volatility over the past week is 6.34% and drops to 3.68% over the past one month. The beta value is 1.52, while the average true range (ATR) is currently pointing at 3.59. The average price target for the stock over the next 12 months is $82.43, with the estimates having a low of $73 and a high of $93. These price ends are -30.12% and -10.97% off the current price level respectively, although investors could be excited at the prospect of a -19.59% if the NVCR share price touches on the median price of $84.
Let’s briefly compare NovoCure (NVCR) stock to its peers. We find that today’s price change of +6.92% and +32.18% over the past 12 months for NVCR competes that of Teladoc Health Inc (TDOC), which has seen its stock price rise 0.7% in the latest trading session and is +185.67% over the last one year. Another of its peers Avantor Inc (AVTR) has dropped -0.82% today, and is +42.22% up over the past year, while Ppd Inc (PPD) is also up 6.92% yet its price remains in the green at 32.18% over the same period. Teladoc has a P/E ratio of 0 compared to NovoCure’s 34820 and Avantor’s 92.99. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.52% and 0.01%, respectively, in early deals.